111 related articles for article (PubMed ID: 385948)
21. Modifying the biological response to acute myeloid leukemia I. BCG, allogeneic leukemic cells and spontaneous cytotoxicity.
Arends-Merino A; Sjögren AM; Reizenstein P
Anticancer Res; 1983; 3(4):239-41. PubMed ID: 6576728
[TBL] [Abstract][Full Text] [Related]
22. BCG immunotherapy in chronic myelocytic leukemia.
Kardaszewicz E; Siejeńska L
Pol Med Sci Hist Bull (1973); 1976; 15(2):225-9. PubMed ID: 1066660
[TBL] [Abstract][Full Text] [Related]
23. [Non-lymphoblastic acute leukaemia: maintenance therapy by trial of a combination of chemo- and immunotherapy (author's transl)].
Sébahoun G; Gastaut JA; Imbert-Xeridat C; Favre R; Carcassonne Y
Nouv Presse Med; 1979 Feb; 8(9):663-5. PubMed ID: 377219
[TBL] [Abstract][Full Text] [Related]
24. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
[TBL] [Abstract][Full Text] [Related]
25. Does BCG vaccination protect the newborn and young infants?
ten Dam HG; Hitze KL
Bull World Health Organ; 1980; 58(1):37-41. PubMed ID: 6991146
[TBL] [Abstract][Full Text] [Related]
26. [Results of immunotherapy of acute leukemias with BCG vaccine of Polish production].
Kardaszewicz E; Japa J
Acta Haematol Pol; 1975; 6(2):149-55. PubMed ID: 1057344
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in acute leukemias. Possible applications in children.
Mahoney DH; Starling KA
Am J Pediatr Hematol Oncol; 1981; 3(4):410-8. PubMed ID: 7036781
[TBL] [Abstract][Full Text] [Related]
29. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
[TBL] [Abstract][Full Text] [Related]
30. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
31. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
[TBL] [Abstract][Full Text] [Related]
32. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).
Giaccone G; Debruyne C; Felip E; Chapman PB; Grant SC; Millward M; Thiberville L; D'addario G; Coens C; Rome LS; Zatloukal P; Masso O; Legrand C
J Clin Oncol; 2005 Oct; 23(28):6854-64. PubMed ID: 16192577
[TBL] [Abstract][Full Text] [Related]
33. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
34. Acute myeloid and lymphoblastic leukemia in adults. The course of the disease in 315 patients from one region, during a ten-year period.
Johnsen HE; Bergmann OJ; Ellegaard J; Bastrup-Madsen P
Dan Med Bull; 1989 Apr; 36(2):189-93. PubMed ID: 2707057
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of active immunotherapy of acute myeloid leukemia.
Mathé G; Musset M; Schwarzenberg L; Hayat M; de Vassal F; Amiel JL; Pouillart P; Misset JL
Biomedicine; 1975 Sep; 23(7):291-3. PubMed ID: 1066168
[TBL] [Abstract][Full Text] [Related]
36. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase.
Baker MA; Taub RN; Carter WH; Davidson M; Sutton DM; Kutas G; Berger S; Watt HJ
Cancer Res; 1984 Jan; 44(1):383-5. PubMed ID: 6360347
[TBL] [Abstract][Full Text] [Related]
38. Chemoimmunotherapy of acute myelogenous leukemia with BCG-cell wall skeleton (CWS).
Araki K; Kawano H; Kishimoto S
Nihon Ketsueki Gakkai Zasshi; 1978 Dec; 41(6):1171-7. PubMed ID: 286492
[No Abstract] [Full Text] [Related]
39. Alloantisera to human leukemic blast cells: detection of leukemia-associated antigens (LAA).
Baker MA; Falk JA; Taub RN
Prog Clin Biol Res; 1977; 16():103-7. PubMed ID: 71741
[No Abstract] [Full Text] [Related]
40. Clinical immunotherapy experiences in the Southeastern Cancer Study Group.
Gordon DS
Dev Biol Stand; 1977 Apr 13-15; 38():567-72. PubMed ID: 344110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
